Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetic Peripheral Neuropathy
New drug application submitted for neuropathic pain treatment
November 24th, 2003
Pfizer Inc has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration seeking approval for pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and herpes zoster (post-herpetic neuralgia), generalized anxiety disorder, and adjunctive therapy for partial seizures in patients with epilepsy. Developed by Pfizer, pregabalin has a unique mechanism of action for potential treatment of certain neurologic and psychiatric disorders. Neuropathic pain and generalized anxiety disorder are highly prevalent, under-diagnosed, and under-treated conditions. There is currently no approved...
Source: Obesity & Diabetes Week (2003-11-24)
|
